Glimepiride Versus Metformin as Monotherapy in Pediatric Patients With Type 2 Diabetes
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To compare the efficacy and safety of glimepiride versus metformin in pediatric subjects with type 2 diabetes inadequately controlled with diet and exercise alone or oral monotherapy. RESEARCH DESIGN AND METHODS—This 26-week, single-blind, active-controlled, multinational study randomized 285 subjects to receive glimepiride (1–8 mg once daily) or metformin (500–1000 mg twice daily) for 24 weeks. The primary end point was mean change in A1C from baseline to week 24. Safety was assessed by incidence of hypoglycemia and other adverse events. RESULTS—Significant reductions from baseline A1C were seen in both the glimepiride (−0.54%, P = 0.001) and metformin (−0.71%, P = 0.0002) groups. A total of 42.4% (56 of 132) and 48.1% (63 of 131) of subjects in the glimepiride and metformin groups, respectively, in the intent-to-treat population achieved A1C <7.0% at week 24. No significant differences were observed between groups in reductions in A1C and self-monitored blood glucose levels, changes in serum lipid concentrations, or hypoglycemia incidence. Significant differences were observed in mean changes from baseline in BMI between groups (0.26 kg/m2 for glimepiride and −0.33 kg/m2 for metformin; P = 0.003). The adjusted mean body weight increase was 1.97 kg for glimepiride and 0.55 kg for metformin (P = 0.005). A hypoglycemic episode with blood glucose <50 mg/dl (<2.8 mmol/l) was experienced by 4.9 and 4.2% of glimepiride- and metformin-treated subjects, respectively. A single severe hypoglycemic event occurred in each group. CONCLUSIONS—Glimepiride reduced A1C similarly to metformin with greater weight gain, and there was comparable safety over 24 weeks in the treatment of pediatric subjects with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a singleblinded RCT, 285 participants aged 8-17 years were randomly assigned to glimepiride or metformin.At 24 weeks, both groups achieved a significant HbA 1c reduction (glimepiride -0•54% [p=0•001] vs metformin -0•71% [p=0•0002]).However, treatment with glimepiride caused greater weight gain (mean BMI change: glimepiride 0•26 kg/m² vs metformin -0•33 kg/m²).79”
From Managing early-onset type 2 diabetes in the individual and at the population level (2025) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Type 2 diabetes in children and adolescents. American Diabetes Association.
(2000) · Diabetes Care · doi:10.2337/diacare.23.3.381 · Cited by 936
Effect of Metformin in Pediatric Patients With Type 2 Diabetes
Jones, K. L., Arslanian, S., Peterokova, V. A., Park, J.-S., & Tomlinson, M. J. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.89 · Cited by 392
Holstein, A., Plaschke, A., & Egberts, E. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.235 · Cited by 264
Cited by
Interventions for treating obesity in children
Oude Luttikhuis, H., Baur, L., Jansen, H., Shrewsbury, V. A., O'Malley, C., Stolk, R. P., & Summerbell, C. D. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001872.pub2 · Cited by 1,531
RetractedType 2 Diabetes in Children and Adolescents
(2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.02.035 · Cited by 926
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 434
Metadata
- Authors
- Gottschalk, M., Danne, T., Vlajnic, A., & Cara, J. F.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-04-01
- Volume
- 30
- Issue
- 4
- Pages
- 790-794
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2056520796
- Cited by
- 143
- References
- 4
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.